



(11)

EP 2 362 226 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
G01N 33/68 ^(2006.01) **C12Q 1/34** ^(2006.01)
A61P 25/28 ^(2006.01)

(48) Corrigendum issued on:
06.04.2016 Bulletin 2016/14

(45) Date of publication and mention
of the grant of the patent:
17.02.2016 Bulletin 2016/07

(21) Application number: **10187871.8**

(22) Date of filing: **07.03.2006**

(54) **Diagnostic method for neurodegenerative diseases based on measurement of SIRT1 levels or activity**

Diagnostisches Verfahren für neurodegenerative Krankheiten basierend auf der Messung von SIRT1 Spiegel oder Aktivität

Méthode diagnostique pour maladies neurodégénératives basée sur la mesure des niveaux ou de l'activité de SIRT1

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR**

(30) Priority: **07.03.2005 US 74374**

(43) Date of publication of application:
31.08.2011 Bulletin 2011/35

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
06737459.5 / 1 863 461

(73) Proprietors:
• **President and Fellows of Harvard College
Cambridge, MA 02138 (US)**
• **Biomol International L.P.
Plymouth Meeting, PA 19462-1202 (US)**

(72) Inventors:
• **Sinclair, David
Chestnut Hill, MA 02467 (US)**

- **Tsai, Li-huei
Cambridge, Massachusetts 02138 (US)**
- **Nguyen, Minh
Calgary, Alberta T2P 5P6 (US)**
- **Howitz, Konrad
Allentown, Pennsylvania 18104 (US)**
- **Zipkin, Robert
Wynnewood, Pennsylvania 19096 (US)**
- **Bitterman, Kevin J.
Boston, MA 02118 (US)**

(74) Representative: **Lee, Nicholas John et al
Kilburn & Strode LLP
20 Red Lion Street
London WC1R 4PJ (GB)**

(56) References cited:
WO-A-2005/002555 WO-A-2006/068656

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 362 226 B8

- PORCU M ET AL: "The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 26, no. 2, 1 February 2005 (2005-02-01), pages 94-103, XP004727629, ISSN: 0165-6147, DOI: DOI:10.1016/J.TIPS.2004.12.009
- ARAKI T ET AL: "Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 305, 13 August 2004 (2004-08-13), pages 1010-1013, XP003001697, ISSN: 0036-8075, DOI: DOI:10.1126/SCIENCE.1098014